Search results for " coro"

showing 10 items of 1850 documents

COVID 19-Induced Smell and Taste Impairments: Putative Impact on Physiology

2021

This article is part of the Research Topic "The Tribute of Physiology for the Understanding of COVID-19 Disease".; International audience; Smell and taste impairments are recognized as common symptoms in COVID 19 patients even in an asymptomatic phase. Indeed, depending on the country, in up to 85-90% of cases anosmia and dysgeusia are reported. We will review briefly the main mechanisms involved in the physiology of olfaction and taste focusing on receptors and transduction as well as the main neuroanatomical pathways. Then we will examine the current evidences, even if still fragmented and unsystematic, explaining the disturbances and mode of action of the virus at the level of the nasal …

0301 basic medicineTaste2019-20 coronavirus outbreakFood intakeCoronavirus disease 2019 (COVID-19)[SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]PhysiologyAnosmiaPhysiologyfeeding behaviorOlfactionReviewlcsh:Physiologytaste03 medical and health sciences0302 clinical medicinePhysiology (medical)[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]medicinesmelllcsh:QP1-981business.industryCOVID-193. Good healthDysgeusia[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition030104 developmental biologymedicine.symptomphysiopathologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionTransduction (physiology)COVID 19030217 neurology & neurosurgeryFrontiers in Physiology
researchProduct

Thrombo-Inflammation in Cardiovascular Disease

2020

AbstractThrombo-inflammation describes the complex interplay between blood coagulation and inflammation that plays a critical role in cardiovascular diseases. The third Maastricht Consensus Conference on Thrombosis assembled basic, translational, and clinical scientists to discuss the origin and potential consequences of thrombo-inflammation in the etiology, diagnostics, and management of patients with cardiovascular disease, including myocardial infarction, stroke, and peripheral artery disease. This article presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following topics: (1) challenges of the endothelial cell barrier; (2) circulating …

0301 basic medicineVENOUS THROMBOSISmedicine.medical_specialtypulmonary embolismNeutrophilsIschemiaISCHEMIA-REPERFUSION INJURYDisease030204 cardiovascular system & hematologyCATHETER-DIRECTED THROMBOLYSIS03 medical and health sciences0302 clinical medicinePERIPHERAL ARTERY-DISEASEMedicineAnimalsHumansPlateletMyocardial infarctionDEEP-VEIN THROMBOSIScoagulationIntensive care medicineStrokeBlood CoagulationExpert Testimonythrombosisbusiness.industryACUTE CORONARY SYNDROMESNEUTROPHIL EXTRACELLULAR TRAPSHematologyNeutrophil extracellular trapsVenous ThromboembolismACTIVATABLE FIBRINOLYSIS INHIBITORmedicine.diseaseAtherosclerosisThrombosisstrokeImmunity Innate3. Good healthVenous thrombosis030104 developmental biologymyocardial infarctionTISSUE FACTORCardiovascular DiseasesinflammationplateletsEndothelium VascularbusinessSUBCLINICAL LEAFLET THROMBOSISThrombosis and Haemostasis
researchProduct

Vitamin D and Cardiovascular Health

2021

The principal source of vitamin D in humans is its biosynthesis in the skin through a chemical reaction dependent on sun exposure. In lesser amounts, the vitamin can be obtained from the diet, mostly from fatty fish, fish liver oil and mushrooms. Individuals with vitamin D deficiency, defined as a serum level of 25 hydroxyvitamin D < 20 ng/dl, should be supplemented. Vitamin D deficiency is a prevalent global problem caused mainly by low exposure to sunlight. The main role of 1,25 dihydroxyvitamin D is the maintenance of calcium and phosphorus homeostasis. However, vitamin D receptors are found in most human cells and tissues, indicating many extra-skeletal effects of the vitamin, particula…

0301 basic medicineVitaminmedicine.medical_specialtyVitamina DEnfermedad cardiovascularchemistry.chemical_element030209 endocrinology & metabolismCalciumCritical Care and Intensive Care Medicinemedicine.disease_causevitamin D deficiencyNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemInternal medicineHipertensiónmedicineVitamin D and neurologyHumansSupplementsVitamin D030109 nutrition & dieteticsNutrition and DieteticsEnfermedad coronariabusiness.industryEndothelial functionVitamin D Deficiencymedicine.diseaseCardiovascular diseaseCoronary heart diseaseEndocrinologyDietéticachemistryCardiovascular DiseasesNutriciónHypertensionNarrative ReviewbusinessHomeostasisOxidative stress
researchProduct

Effects of ewes grazing sulla or ryegrass pasture for different daily durations on forage intake, milk production and fatty acid composition of cheese

2016

Sulla (Sulla coronarium L.) forage is valued for its positive impact on ruminant production, in part due to its moderate content of condensed tannin (CT). The duration of daily grazing is a factor affecting the feed intake and milk production of ewes. In this study, the effects of grazing sulla pasture compared with annual ryegrass, and the extension of grazing from 8 to 22 h/day, were evaluated with regard to ewe forage intake and milk production, as well as the physicochemical properties and fatty acid (FA) composition of cheese. During 42 days in the spring, 28 ewes of the Comisana breed were divided into four groups (S8, S22, R8 and R22) that grazed sulla (S) or ryegrass (R) for 8 (0800…

0301 basic medicinecheese fatty acids; daily grazing duration; dairy ewes; sheep milk; Sulla coronarium; Animal Science and ZoologyPastureEatingchemistry.chemical_compoundCheeseCaseinGrazingSheep milkchemistry.chemical_classificationgeography.geographical_feature_categoryRumenic acidfood and beveragesFabaceaecheese fatty acids04 agricultural and veterinary sciencesAnimal cultureMilkFatty Acids UnsaturatedAnimal Nutritional Physiological PhenomenaFemaledairy ewesPolyunsaturated fatty acidSettore AGR/19 - Zootecnica SpecialeSulla coronariumSettore AGR/13 - Chimica AgrariaForageBiologycheese fatty aciddairy eweSF1-1100sheep milk03 medical and health sciencesAnimal scienceLoliumAnimalsLactationDry mattergeographySheep030109 nutrition & dietetics0402 animal and dairy scienceAnimal Feed040201 dairy & animal scienceDietchemistryAgronomyAnimal Science and Zoologydaily grazing durationanimal
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses

2018

Background Nanoparticle (NP)–based vaccines are attractive immunotherapy tools because of their capability to codeliver antigen and adjuvant to antigen-presenting cells. Their cellular distribution and serum protein interaction ("protein corona") after systemic administration and their effect on the functional properties of NPs is poorly understood. Objectives We analyzed the relevance of the protein corona on cell type–selective uptake of dextran-coated NPs and determined the outcome of vaccination with NPs that codeliver antigen and adjuvant in disease models of allergy. Methods The role of protein corona constituents for cellular binding/uptake of dextran-coated ferrous nanoparticles (DE…

0301 basic medicineendocrine systemOvalbuminCpG OligodeoxynucleotideT-Lymphocytesmedicine.medical_treatmentImmunologyMice Transgenic02 engineering and technologyComplement factor IComplement receptor03 medical and health sciencesImmune systemAntigenLectinsHypersensitivitymedicineAnimalsImmunology and AllergyFerrous CompoundsAntigensAnaphylaxisB-LymphocytesDrug CarriersMice Inbred BALB CVaccinesChemistryDextransImmunotherapyrespiratory system021001 nanoscience & nanotechnologyComplement systemMice Inbred C57BL030104 developmental biologyOligodeoxyribonucleotidesImmunologyNanoparticlesFemaleProtein Corona0210 nano-technologyAdjuvantJournal of Allergy and Clinical Immunology
researchProduct

The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery

2018

Nanocarriers (NC) are very promising tools for cancer immunotherapy. Whereas conventional vaccines are based on the administration of an antigen and an adjuvant in an independent fashion, nanovaccines can facilitate cell-specific co-delivery of antigen and adjuvant. Furthermore, nanovaccines can be decorated on their surface with molecules that facilitate target-specific antigen delivery to certain antigen-presenting cell types or tumor cells. However, the target cell-specific uptake of nanovaccines is highly dependent on the modifications of the nanocarrier itself. One of these is the formation of a protein corona around NC after in vivo administration, which may potently affect cell-speci…

0301 basic medicinelcsh:Immunologic diseases. AllergyMini Reviewmedicine.medical_treatmentImmunologyCellcell-specific targetingProtein Corona02 engineering and technology03 medical and health sciencesprotein coronaAntigenCancer immunotherapyIn vivoNeoplasmsmedicineHumansImmunology and AllergyReceptors ImmunologicnanocarriersChemistryImmunotherapy021001 nanoscience & nanotechnologyBody FluidsTreatment Outcome030104 developmental biologymedicine.anatomical_structureCancer researchNanoparticlesimmunotherapyNanocarriers0210 nano-technologylcsh:RC581-607Adjuvantcancer vaccinesProtein BindingFrontiers in Immunology
researchProduct

Galectin-3 in acute coronary syndrome

2017

Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This art…

0301 basic medicinemedicine.medical_specialtyAcute coronary syndromeAcute coronary syndrome; AMI; Galectin-3; Heart failure; Myocardial infarction; Prognosis; Acute Coronary Syndrome; Atherosclerosis; Biomarkers; Galectin 3; Heart Failure; Humans; Myocardial Infarction; Prognosis; Evidence-Based Medicine; Clinical BiochemistryPrognosiGalectinsGalectin 3Clinical BiochemistryMyocardial InfarctionDisease030204 cardiovascular system & hematologyAMI03 medical and health sciences0302 clinical medicineFibrosismedicineHumansGalectin-3Myocardial infarctionIntensive care medicineHeart FailureEvidence-Based Medicinebiologybusiness.industryGold standardGeneral MedicineBlood ProteinsBiomarkermedicine.diseaseAtherosclerosisPrognosisTroponin030104 developmental biologyGalectin-3Heart failureAtherosclerosibiology.proteinAcute coronary syndromebusinessBiomarkersHuman
researchProduct

Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study

2016

Introduction Stratification for subsequent coronary events among patients with coronary artery disease (CAD) is of considerable interest because of the potential to guide secondary preventive therapies. Recently, we identified eight microRNAs (miRNAs), which facilitated acute coronary syndrome (ACS) diagnosis. In this study, we aimed to evaluate their potential role as prognostic biomarkers for cardiovascular disease. Methods The serum concentrations of eight candidate miRNAs -miR-19a, miR-19b, miR-132, miR-140-3p, miR-142-5p, miR-150, miR-186, and miR-210 were measured in a cohort of 1112 patients with documented CAD—including 430 patients with ACS and 682 patients with stable angina pecto…

0301 basic medicinemedicine.medical_specialtyAcute coronary syndromePathologyProportional hazards modelbusiness.industryDisease030204 cardiovascular system & hematologymedicine.diseaseCoronary artery disease03 medical and health sciencesCirculating MicroRNA030104 developmental biology0302 clinical medicineInternal medicineCohortmedicineCardiologyBiomarker (medicine)Cardiology and Cardiovascular MedicineRisk assessmentbusinessEuropean Heart Journal
researchProduct

Managing cancer patients during the COVID-19 pandemic:an ESMO multidisciplinary expert consensus

2020

We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one patient advocate, led by the European Society for Medical Oncology, statements were discussed, amended and voted upon. When consensus could not be reached, the panel revised statements until a consensus was reached. Overall, the expert panel agreed …

0301 basic medicinemedicine.medical_specialtyConsensusCoronavirus disease 2019 (COVID-19)Settore MED/18 - CHIRURGIA GENERALEPneumonia ViraleducationDiseaseMedical OncologyReal-Time Polymerase Chain ReactionSpecial Article03 medical and health sciencesBetacoronavirus0302 clinical medicineMultidisciplinary approachNeoplasmsPandemicGranulocyte Colony-Stimulating FactorMedicineHumansDisease management (health)PandemicsSocieties Medicalbusiness.industrySARS-CoV-2Expert consensusCOVID-19Disease ManagementcovidHematologyTelemedicineEurope030104 developmental biologyOncology030220 oncology & carcinogenesisFamily medicineCancer managementSevere acute respiratory syndrome coronavirusbusinessCoronavirus InfectionsT-Lymphocytes Cytotoxic
researchProduct